French pharmaceutical major Sanofi (NASDAQ: SNY) has signed a partnership agreement with the Pingshan district government in Shenzhen, aiming to accelerate the introduction of innovative vaccines to the Chinese market and to foster the innovative development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA).
Shenzhen’s Focus on Biopharmaceutical Industry Ecosystem
As one of the first national biopharmaceutical industry bases, Shenzhen has long been dedicated to establishing an ecosystem for scientific research and commercial production. The city has been investing significant resources into the research, development, and production of high-end medical devices and innovative medicines, positioning the industry as a new economic growth driver.
Pingshan: The Heartland of Shenzhen’s Biopharmaceutical Industry
Pingshan is recognized as the core area of Shenzhen’s biopharmaceutical industry. Yang Jun, Party secretary of Pingshan district, stated, “We believe that our collaboration with Sanofi will benefit the high-quality development of the biopharmaceutical industry and make it the core engine for industrial growth in the GBA.” This partnership is expected to leverage Sanofi’s expertise and resources to enhance the region’s biopharmaceutical capabilities and contribute to the industry’s growth within the GBA.-Fineline Info & Tech
